EUGENE SUNG KYUN KIM
|Title||Adjunct Associate Professor|
|Institution||Baylor College of Medicine|
|Department||Department of Surgery|
|Address||6701 Fannin, Suite 1210|
Clinical Care Center
Houston TX 77030
Additional Tools and Researcher Information
Dr. Eugene S. Kim’s clinical focus has been pediatric surgical oncology, chest wall deformities, and anorectal malformations. His academic focus has been in basic science oncology research, specifically the development of novel preclinical therapies for neuroblastoma, an aggressive pediatric malignancy.
Dr. Kim’s laboratory has two main areas of interest in the study of neuroblastoma. Dr Kim’s primary area of expertise is the study of antiangiogenic therapies in neuroblastoma. Specifically, Dr. Kim has investigated the dual role of the oncogene MDM2 in neuroblastoma. Dr. Kim has published findings which show that inhibition of MDM2 in neuroblastoma is both antitumoral, via a p53-mediated pathway, and anti-angiogenic, via a p53 independent pathway by modulating the expression of HIF-1a and downstream VEGF. Current studies with MDM2 inhibition in neuroblastoma include the use of a novel and more potent inhibitor of MDM2 (RG7388) in determining the synergy of this drug with mTOR inhibitors as well as the efficacy of this drug in p53-mutant neuroblastoma tumors. Such a discovery may expand the use of these drugs to p53 mutant tumors. We have been selected as a lab to trial this new drug in our preclinical model of neuroblastoma to provide supporting evidence of its efficacy prior to clinical trials in children.
Dr. Kim’s second area of expertise involves the study of a novel cancer stem cell population in neuroblastoma, which is believed tobe the cause of tumor relapse. Recently, our lab in collaboration with Dr. Shohet has isolated and characterized a novel cancer stem cell population in neuroblastoma based on the expression of CD114. As the potential cause of recurrence in this aggressive pediatric malignancy, the cancer stem cell subpopulation in neuroblastoma has significant clinical implications. We are continuing our studies of this CD114+ subpopulation by studying in vitro and in vivo the effect of the ligand to the receptor. The ligand, G-CSF, is a common medication given to children with neuroblastoma as part of their therapy – therefore, there is a concern that part of the treatment for these patients may be inadvertantly leading tuo tumor recurrence. In addition, we are looking to target this subpopulation in animal models as well as examine human tissue to determine and correlate the expression levels of this receptor to clinical outcomes.
Click the "See All" links for more information and interactive visualizations!
People who are also in this person's primary department.